Symposium in memory of Professor Inga Marie Nilsson

Haemophilia

Volumn 7, Issue 4, 2001, Pages 401-410

  Astermark, J ^a   Aledort, L ^a   Berntorp, E ^a   Blomback M ^a   Dahlback B ^a   Freiburghaus, C ^a   Giannelli, F ^a   Ginsburg, D ^a   Holmberg, L ^a   Hoyer, L ^a   Lethagen, S ^a   Ljung, R ^a   Mannucci, P ^a   Mariani, G ^a   Michiels, J J ^a   Nuss, R ^a   Peake, I R ^a   Petersson, C ^a   Petersson, H ^a   Rodriguez Merchan, C ^a   Tengborn, L ^a   Vermylen, L ^a   more..

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Arthropathy; Clotting factor concentrates; Haemophilia; Inhibitors; Prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR CONCENTRATE; BLOOD CLOTTING INHIBITOR; BLOOD DERIVATIVE; DESMOPRESSIN; FIBRINOGEN; HLA ANTIGEN; PROTEIN C; PROTEIN S; VON WILLEBRAND FACTOR;

ANTIDIURESIS; BLEEDING DISORDER; BONE RADIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CPG ISLAND; DISEASE SEVERITY; DRUG EXPOSURE; DRUG HALF LIFE; FEMALE; FRAMESHIFT MUTATION; GENE DELETION; GENE MUTATION; GENETIC DISORDER; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; IMMUNOASSAY; IMMUNOLOGICAL TOLERANCE; IMMUNOPROPHYLAXIS; MALE; MEDICAL EDUCATION; MISSENSE MUTATION; MUSCULOSKELETAL DISEASE; NONSENSE MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESSOR RESPONSE; PRIORITY JOURNAL; REVIEW; SYMPOSIUM; THROMBOEMBOLISM; VON WILLEBRAND DISEASE; X CHROMOSOME;

EID: 0034920337     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2001.00524.x     Document Type: Article

References (62)

1. Willebrand's disease and its correction with human plasma fraction 1-0
2. On an inherited autosomal hemorrhagic diathesis with anti-hemophilic globulin (AHG) deficiency and prolonged bleeding time
3. Treatment of hemophilia A with human antihemophilic globulin
4. V Willebrand's disease in Sweden. Its pathogenesis and treatment
5. Clinical experience with a Swedish factor IX concentrate
6. Immunoadsorption for removal of inhibitors: Update on treatment in Malmö-Lund between 1980 and 1995
7. Management of patients with inhibitory antibodies
8. Tolerance induction using the Malmö treatment model 1982-95
9. The Malmö model for immune tolerance induction: Impact of previous treatment on outcome
10. Epitope specificity and inactivation mechanisms of factor VIII inhibitor antibodies
11. Histocompatibility antigen patterns in haemophilic patients with factor VIII antibodies
12. Relationship of major histocompatibility complex class II genes to inhibitor antibody formation in haemophilia
13. HLA class II profile: A weak determinant of factor VIII inhibitor development in severe haemophilia A
14. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII
15. Haemophilia A: Mutation type determines risk of inhibitor formation
16. Genetic basis of inhibitor development in haemophilia A
17. Factor VIII gene inversions in severe hemophilia A. Results of an international consortium study
18. Factor VIII structure and function
19. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation
20. Characterization of the immune response to factor VIII using hemophilia A mice
21. International immune tolerance registry, 1997 update
22. Inversions of the factor VIII gene in Swedish patients with severe haemophilia A
23. Origin of mutation in sporadic cases of haemophilia A
24. Gene mutations and inhibitor formation in patients with hemophilia B
25. Hemophilia A database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene
26. A rapid method for haemophilia B mutation detection using conformation sensitive gel electrophoresis
27. Rapid screening of the factor VIII gene for mutations using multiplex PCR and conformation sensitive gel electrophoresis
28. Mutation rates in humans I. Overall and sex-specific rates obtained from a population study of hemophilia B
29. Mutation rates in humans II. Sporadic mutation-specific rates and rate of detrimental human mutations inferred from hemoiphilia B
30. Haemophilia in Sweden; VII. Incidence, treatment and prophylaxis of arthropathy and other musculosceletal manifestations of haemophilia A and B
31. Hemophilic arthropathy
32. Hemophilic arthropathy: Current concepts of pathogenesis and management
33. Diagnostic imaging in hemophilia
34. Utility of magnetic resonance imaging for management of hemophilic arthropathy in children
35. MRI findings in hemophilic joints treated with radiosynoviorthesis with development of an MRI scale of joint damage
36. Twenty-five years' experience of prophylactic treatment in severe hemophilia A and B
37. Primary prophylaxis in severe hemophilia should be started at early age but can be individualized
38. A longitudinal study of orthopaedic outcomes for severe factor VIII-deficient haemophiliacs
39. A new pharmacological approach to the management of hemophilia and von Willebrand disease
40. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP
41. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease
42. Intranasal and intravenous administration of desmopressin: Effect on FVIII/vWF, pharmacokinetics and reproducibility
43. Platelet aggregation induced by 1-deamino-8-D-arginine vasopressin (DDAVP) in type IIB von Willebrand disease
44. Desmopressin (DDAVP) in the treatment of bleeding disorders: The first twenty years
45. Haemostatic and replacement therapy in von Willebrand disease
46. The molecular biology of von Willebrand disease
47. von Willebrand disease
48. The effect of ABO blood group on the diagnosis of von Willebrand disease
49. Mvwf, a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase
50. Acquired von Willebrand disease
51. Acquired von Willebrand syndromes: Clinical features, etiology, pathophysiology, classification and management
52. Antifibrinolytic activity and metabolism of ε-aminocaproic acid in man
53. Clinical experiences with ε-aminocaproic acid (ε-ACA) as an antifibrinolytic agent
54. Fibrinolysis induced by strepto-kinase in man
55. Vitamin K dependent modifications of glutamic acid residues in prothrombin
56. A new vitamin K-dependent protein. Purification from bovine plasma and preliminary characterization
57. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Prediction of a cofactor to activated protein C
58. Mutation in blood coagulation factor V associated with resistance to activated protein C
59. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls
60. Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis
61. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis